Skip to main content
. 2022 Aug 27;14:2545–2559. doi: 10.2147/CMAR.S370397

Figure 8.

Figure 8

The sensitivity in immunotherapy and chemotherapy between the high and low SLC7A5 expression groups. IC50, half-maximal inhibitory concentration. (A) Higher sensitivity in the low-SLC7A5-expression group than in the high-SLC7A5-expression group. (B) SLC7A5-expression in two chemotherapeutic drugs, paclitaxel and doxorubicin, in breast cancer therapy. (*p < 0.05).